Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Why Curis Fell Off a Cliff on Friday

TheMotleyFool

0 0

Why Curis Fell Off a Cliff on FridayPhoto, wide shot, wide-angle lens, Medical device manufacturer, Blue hour, twilight, cool, ISO1200, slow shutter speed, photo by Michael Light: https://img.theapi.app/temp/3a7f6312-1eee-4702-9005-93cc1e62f970.png

Cancer drug specialist Curis (NASDAQ: CRIS) had a Friday to forget. The biotech's share price took a nearly 37% hit after the company reported some disquieting news about a leading pipeline drug.

Friday morning, Curis published updated data from a phase 1/2 clinical trial of its CA-4948, a drug targeting acute myeloid leukemia and myelodysplastic syndromes. The primary endpoint of the trial, which involved 22 participants, was to determine the treatment's maximum tolerated and recommended dose for a phase 2 study.

Image source: Getty Images.

Source Fool.com

Like: 0

CRIS

Share